Biotech Insights
A Haynes Boone Newsletter
The Biotech Insights newsletter is your go-to resource for staying informed on the latest legal developments in biotechnology. Our Winter newsletter is featured below, as well as links to previous newsletters and information.
Biotech Insights - Winter 2026
Welcome to Haynes Boone’s Biotech Insights! This newsletter is your go-to resource for staying informed on the latest legal developments in biotechnology. Each edition will feature expert analysis of key topics impacting the biotechnology industry, a spotlight on one of our talented team members and details about where to connect with our team at upcoming industry events. We are committed to keeping you informed in this important and rapidly evolving field.
Read the Winter 2026 Biotech Insights here.
A client calls and says, “We’re cooking up a bispecific antibody. We want to mix and match binding sequences like a molecular gastronomy tasting menu. Some will go into CAR-T dishes. And of course, we want patents everywhere—from the United States to Latin America to the Persian Gulf. What ingredients do you need?”
If this sounds familiar, welcome to the Michelin-starred madness of bispecific antibody (bsAb) patenting, where every jurisdiction is a different kitchen with its own rules, recipes and temperamental food critic extraordinaire—aka patent examiner.
Whether you plan on “doing business” in California, selling a business in California, acquiring a business that is a California entity or merging with a business that is in California, the process may appear straightforward. However, business owners, including those in the life sciences industry, commonly overlook multiple issues and considerations related to California.
This is the first article in a two-part series addressing a few key items that life science business owners should consider when dealing with a merger or acquisition in California. Part 1 addresses approval mechanics, corporate governance requirements, minority protections, dissenters’ rights, California’s permit and fairness hearing process and the quasi-California corporation “long-arm” regime.
On Oct. 27, 2025, the U.S. Patent and Trademark Office (USPTO) announced it is offering a Streamlined Claim Set Pilot Program in an effort to further accelerate examination of currently pending applications with a limited number of claims. This Pilot Program supplements the Track One program, which remains in place.
To qualify, a patent applicant must file a timely petition to make special under this new Pilot Program.